GlassScriptPhysician profile
Anne M Paden
NPI 1275509879
$5,272.23
in general payments reported to CMS, 2019-2025
20 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $608 · 2023: $960 · 2024: $1,270 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.47 |
| Education | $142.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,083.37 | 2021-2025 | |
| Axsome Therapeutics, INC. | $712.35 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $403.78 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $337.45 | 2023-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $320.25 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.99 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $262.69 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $146.27 | 2021-2025 | Trintellix |
| Alkermes, INC. | $144.31 | 2022-2025 | Lybalvi, Aristada |
| Corium, LLC | $132.40 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $113.64 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $109.90 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $64.13 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $38.88 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $33.90 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $28.46 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $25.74 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.31 | 2023 | Quviviq |
| Neos Therapeutics, LP | $14.87 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Paden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.